Refissa is a prescription medicine that may reduce fine facial wrinkles and mottled hyperpigmentation in patients who also protect their skin from the sun and wear sunscreen daily. Refissa does not eliminate wrinkles, repair sun damaged skin or reverse photo-aging. Do not use if you are pregnant, attempting pregnancy, or nursing. Do not use if taking medicines that may increase your sensitivity to sunlight. Use of Refissa may make your skin more likely to burn from sunlight. Refissa, early in treatment, may cause redness, itching, burning, stinging and peeling. If you have questions about side effects, contact your physician. If you are uncomfortable, use less medication and decrease the frequency of application. If discomfort is still significant, discontinue use and consult your physician. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Please see full Prescribing Information and Patient Package Insert. Refissa is a trademark of Spear Pharmaceuticals, Inc. © 2009 Spear Dermatology Products.
In these trials, the fine wrinkles, mottled hyperpigmentation, and tactile roughness of the facial skin were thought to be
perpigmentation, and tactile roughness of facial skin with the use of comprehensive skin care and sun avoidance
DERMAL HISTOLOGIC PATTERN.

INDICATIONS AND USAGE:

- Refissa® Cream, USP 0.05% is a retinoid dermal cream that contains Tretinoin (vitamin A acid) in an emollient vehicle to treat fine wrinkles,

- Neoplasms has been established.

- The safety and effectiveness of Refissa for people over age 50 or with darker skin coloration has not been proven.

- Most of the improvement in these signs was noted during the first 24 weeks of therapy. Thereafter, therapy primarily

- The Tretinoin Cream, USP (Emollient) 0.05% are administered in the morning and evening, once or twice daily, to

- There are no major malformations were reported at doses of 10 mg/kg/day or greater, but none were observed at 5 mg/kg/day (1000

- Application of larger amounts of medication than recommended will not result in more rapid or better

- Tretinoin Cream, USP (Emollient) 0.05% should not be administered if the patient is also taking drugs known to be photosensitizers (e.g.,

- Local reactions such as peeling, dry skin, burning, stinging, erythema, and pruritus were reported by almost all

- The drugs should be used with the advice and under the supervision of qualified medical practitioners.

- You should use Refissa® Cream with local trials. In these studies involving 179 patients who applied Tretinoin Cream, USP (Emollient) 0.05%

- The Tretinoin Cream, USP (Emollient) 0.05% should be kept out of the reach of children.

- Refissa® Cream, USP 0.05% is contraindicated in women who are pregnant or planning to become pregnant (see

- The National Institute for Clinical Excellence in the United Kingdom has recommended that the use of topical

- In double-blind, vehicle-controlled studies involving 179 patients who applied Tretinoin Cream, USP (Emollient) 0.05%

- Refissa® Cream, USP 0.05% may increase your sensitivity to sunlight (see below).

- Tretinoin is a serious medication that may help but not treat fine wrinkles, spotty skin discoloration, and rough

- The safety and effectiveness of Refissa for people over age 50 or with darker skin coloration has not been established.

- In these trials, the fine wrinkles, mottled hyperpigmentation, and tactile roughness of the facial skin were thought to be

- The Tretinoin Cream, USP (Emollient) 0.05% should be kept out of the reach of children.

- This leaflet summarizes the most important information about Refissa. If you would like more information, talk to your

- The National Institute for Clinical Excellence in the United Kingdom has recommended that the use of topical

- Refissa® Cream, USP 0.05% is contraindicated in women who are pregnant or planning to become pregnant (see

- Neoplasms has been established.

- DERMAL HISTOLOGIC PATTERN.

- The safety and effectiveness of Refissa for people over age 50 or with darker skin coloration has not been established.

- The safety and effectiveness of Refissa for people over age 50 or with darker skin coloration has not been established.

- There is no evidence of atypical changes in female CD-1 mice. In these studies, the fine wrinkles, mottled hyperpigmentation, and tactile

- When you use Refissa, improvement in fine wrinkling, spotty skin discoloration and rough skin is not immediate and will gradually

- Must be out in the sun for long periods, you must use extreme caution.

- When you use Refissa, improvement in fine wrinkling, spotty skin discoloration and rough skin is not immediate and will gradually

- The safety and effectiveness of Refissa for people over age 50 or with darker skin coloration has not been established.

- The National Institute for Clinical Excellence in the United Kingdom has recommended that the use of topical

- The Tretinoin Cream, USP (Emollient) 0.05% should be kept out of the reach of children.

- You should use Refissa® Cream with local trials. In these studies involving 179 patients who applied Tretinoin Cream, USP (Emollient) 0.05%

- The drugs should be used with the advice and under the supervision of qualified medical practitioners.

- The drugs should be used with the advice and under the supervision of qualified medical practitioners.

- The National Institute for Clinical Excellence in the United Kingdom has recommended that the use of topical

- The drugs should be used with the advice and under the supervision of qualified medical practitioners.

- You should use Refissa® Cream with local trials. In these studies involving 179 patients who applied Tretinoin Cream, USP (Emollient) 0.05%

- You should use Refissa® Cream with local trials. In these studies involving 179 patients who applied Tretinoin Cream, USP (Emollient) 0.05%

- You should use Refissa® Cream with local trials. In these studies involving 179 patients who applied Tretinoin Cream, USP (Emollient) 0.05%

- You should use Refissa® Cream with local trials. In these studies involving 179 patients who applied Tretinoin Cream, USP (Emollient) 0.05%

- You should use Refissa® Cream with local trials. In these studies involving 179 patients who applied Tretinoin Cream, USP (Emollient) 0.05%

- You should use Refissa® Cream with local trials. In these studies involving 179 patients who applied Tretinoin Cream, USP (Emollient) 0.05%